Your browser doesn't support javascript.
loading
Challenges and Opportunities for Nucleic Acid Therapeutics.
Corey, David R; Damha, Masad J; Manoharan, Muthiah.
Afiliación
  • Corey DR; Department of Pharmacology and Biochemistry, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Damha MJ; Department of Chemistry, McGill University, Montreal, Canada.
  • Manoharan M; Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
Nucleic Acid Ther ; 32(1): 8-13, 2022 02.
Article en En | MEDLINE | ID: mdl-34931905
After decades overcoming difficult problems, antisense oligonucleotide (ASO), duplex RNA (siRNA), and messenger RNA (mRNA) nucleic acid therapeutic strategies are finally demonstrating clinical benefits. This success presents new challenges. What goals remain for basic research? Will there be an explosion of clinical applications that benefit many patients with different diseases, or will success be restricted to diseases that are ideal for the application of current technologies? The aim of this perspective is to describe a selection of the major goals for the next decade.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligonucleótidos / Oligonucleótidos Antisentido Límite: Humans Idioma: En Revista: Nucleic Acid Ther Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Oligonucleótidos / Oligonucleótidos Antisentido Límite: Humans Idioma: En Revista: Nucleic Acid Ther Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos